Contact
searchSearch
HMP Global

Peripheral Arterial Disease Videos

Tim Wittig, MD
AMP 2026
Primary Outcomes of the MOTIV BTK Sirolimus-Eluting Bioresorbable Vascular Scaffold for the Treatment of Infrapopliteal Lesions
10/20/2026
Tim Wittig, MD
Dr Tim Wittig fdiscusses his presentation on the MOTIV BTK sirolimus-eluting bioresorbable vascular scaffold (REVA Medical).
Dr Tim Wittig fdiscusses his presentation on the MOTIV BTK sirolimus-eluting bioresorbable vascular scaffold (REVA Medical).
Dr Tim Wittig fdiscusses his...
10/20/2026
Vascular Disease Management
Mike Watts, MD, FSIR
AMP 2026
Healing That Lasts: Real-World 90-Day Outcomes Demonstrating the Durability of Serration Remodeling Therapy
10/06/2026
Mike Watts, MD, FSIR
Mike Watts, MD, FSIR, discusses his AMP 2026 presentation on serration remodeling therapy.
Mike Watts, MD, FSIR, discusses his AMP 2026 presentation on serration remodeling therapy.
Mike Watts, MD, FSIR, discusses...
10/06/2026
Vascular Disease Management
Dr Anahita Dua speaks at AMP 2026
AMP 2026
The Changing Face of Chronic Limb-Threatening Ischemia: Global Epidemiology and the Untold Data Story
09/10/2026
Anahita Dua, MD, MS, MBA, FACS
Dr Anahita Dua discusses the changing face of CLTI.
Dr Anahita Dua discusses the changing face of CLTI.
Dr Anahita Dua discusses the...
09/10/2026
Vascular Disease Management
Dr N'Dandu speaks at AMP 2026
AMP 2026
Woundosome for Wound Healing
09/01/2026
Zola N'Dandu, MD
Dr Zola N'Dandu discusses the woundosome concept and its impact on outcomes in patients with chronic limb-threatening ischemia.
Dr Zola N'Dandu discusses the woundosome concept and its impact on outcomes in patients with chronic limb-threatening ischemia.
Dr Zola N'Dandu discusses the...
09/01/2026
Vascular Disease Management
Marianne Brodmann, MD, speaks at AMP 2026.
AMP 2026
Long-Term Evidence From DEEPER OUS
08/25/2026
Marianne Brodmann, MD
Dr Marianne Brodmann discusses the latest results from the DEEPER OUS trial.
Dr Marianne Brodmann discusses the latest results from the DEEPER OUS trial.
Dr Marianne Brodmann discusses...
08/25/2026
Vascular Disease Management

About Us

Vascular Disease Management™ (VDM), the official media partner of the International Symposium on Endovascular Therapy (ISET) and the Amputation Prevention Symposium (AMP), educates readers on the latest advancements in endovascular treatment strategies. 

Learn more about ISET and AMP and register for the events here:

ISET logo

AMP logo

Subscribe Now!

Vascular Disease Management Newsletter

News

LAA Occluders
Late-Breaking One-Year Data Show Abbott's Next-Generation Amulet 360™ Device Continues to Demonstrate High Rates of Left Atrial Appendage Closure and Low Incidence of Stroke
11/03/2026
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year...
11/03/2026
Vascular Disease Management
Intravascular Lithotripsy
Abbott's TECTONIC Clinical Trial Demonstrates Strong 30-day Outcomes and High Procedural Success for Its Investigational SonicForce™ Coronary Intravascular Lithotripsy System
11/03/2026
11/03/2026
Vascular Disease Management
Stroke Clinical Trials
Could A Drug for Leg Cramps Prevent a Second, Deadlier Stroke? 
10/30/2026
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the...
10/30/2026
Cath Lab Digest
Radiation Safety
Rampart Launches Vanguard™ at TCT 2026, Extending Total-Body Radiation Protection to Interventional Imagers
10/29/2026
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table...
10/29/2026
Vascular Disease Management
Peripheral Arterial Bleeds
Instylla's Embrace® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds
10/29/2026
10/29/2026
Vascular Disease Management
Large-Bore Closure
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
10/27/2026
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system...
10/27/2026
Cath Lab Digest
FDA Approvals
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
10/20/2026
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra,...
10/20/2026
Cath Lab Digest
Vertex PE System (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Announces Publication of SPIRARE II Pivotal Trial Results Showing Vertex Thrombectomy System Normalized Hemodynamics in 50% of Pulmonary Embolism Patients
10/19/2026
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the...
10/19/2026
Cath Lab Digest
Endovascular Aortic Repair
FDA Approves GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis for Expanded use in FEVAR and BEVAR
10/15/2026
10/15/2026
Vascular Disease Management
Deep Learning
Deep Learning Model Predicts Hepatocellular Carcinoma Progression Following Transarterial Chemoembolization
10/09/2026
Laura Simson, MA
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining...
10/09/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use